CRISPR-Based Gene Editing Therapeutics

ANMD-MRS9-087 · Advanced Therapeutics & Biomanufacturing

A Global Sustainability Due Diligence & Market Research Study

History 2020–2024 · Base Year 2025 · Forecast 2025–2032 · Outlooks 2035 / 2040 / 2050 · Currency US$

WHY THIS REPORT

CRISPR-based gene editing therapeutics are the precision-medicine frontier proven by the first approved gene-edited therapy — the ex-vivo, in-vivo, base-editing and prime-editing approaches that correct, disrupt or modulate disease-causing genes. This decision-grade study sizes the global market three ways — value, patients treated and dose volume — across editing type, delivery setting and application, across seven regions and four scenarios to 2032, with outlooks to 2050.

SUSTAINABILITY & SDG IMPACT — THE ANMD LENS

Sustainability is this report's backbone, not an afterthought. Beyond efficacy, gene editing offers potentially curative, one-time treatment with profound access, equity and governance implications.

Mapped Sustainable Development Goals:

SDG 3	SDG 9	SDG 10	SDG 12	SDG 17
Good Health & Well-Being	Industry, Innovation & Infrastructure	Reduced Inequalities	Responsible Consumption	Partnerships for the Goals

Measurable sustainability outcomes assessed:

- Potentially curative, one-time treatment value
- Equitable access to curative therapies
- Ethical, governance and long-term-safety considerations
- Manufacturing footprint and safety monitoring as material risks

Framework alignment: Double materiality mapped to GRI, SASB, ISSB, TCFD, TNFD, CSRD and the EU Taxonomy, with greenwashing and SDG-washing screens applied throughout.

WHAT'S INSIDE AT A GLANCE

53 Chapters	**9** Report Parts	**7** Regions Covered	**40+** Country Markets
2025–32 Forecast Horizon	**4** Forward Scenarios	**20+** Companies Profiled	**5** SDGs Mapped

REPORT COVERAGE

Geographic scope: North America, Europe, Asia Pacific, Latin America, Africa, Middle East and Rest of World — with named country intelligence. North America leads the field; Europe holds a pioneer position behind the first approved gene-edited therapy; Asia Pacific is building capability; other regions assessed on their own merits for access and capacity-building.

© Anew Market Dynamics

MARKET OVERVIEW

From first approval to in-vivo pipeline — where precision editing becomes potentially curative medicine.

CRISPR therapeutics are transitioning from validation to pipeline. Demand is driven by the first approval, advancing in-vivo delivery, and next-generation base- and prime-editing — with delivery and specificity central to expanding beyond ex-vivo blood disorders. The market is read three ways — value, patients treated and dose volume — and forecast under four scenarios, each region reported separately.

- **North America leads the field** — United States, anchoring ex-vivo and in-vivo editing pipelines
- **Europe holds a pioneer position** — Switzerland, behind the first approved gene-edited therapy
- **Asia Pacific is building capability** — China and Japan, on research and manufacturing capacity
- **In-vivo delivery is the differentiator** — moving editing from ex-vivo cells to LNP- and AAV-delivered in-body treatment unlocks far broader indications

REGIONAL OUTLOOK

Across seven reporting regions, the report separates leading markets from high-growth and emerging ones — each profiled in full rather than aggregated into Rest of World.

Region	Stage	Lead Markets & Drivers
North America	Field leader	United States — ex-vivo & in-vivo editing pipelines
Europe	Pioneer position	Switzerland — first approved gene-edited therapy
Asia Pacific	Building capability	China, Japan — research & manufacturing capacity
Latin America	Frontier	Brazil — research collaboration
Africa	Frontier	South Africa — sickle-cell trial relevance
Middle East	Emerging	Israel, UAE — research & sovereign investment

KEY MARKET DRIVERS & RESTRAINTS

Drivers	Restraints
• First-approval validation & momentum	• Delivery & tissue-targeting limits
• In-vivo delivery (LNP, AAV) advances	• Off-target & safety considerations
• Base- & prime-editing precision gains	• Manufacturing & CMC complexity
• Potential one-time curative value	• Regulatory & ethical scrutiny
• Expanding target & indication scope	• Reimbursement for one-time cures

© Anew Market Dynamics

SEGMENTATION SNAPSHOT

By Editing Type	Ex-vivo CRISPR · in-vivo CRISPR · base-editing · prime-editing · epigenetic editing
By Delivery Setting	Ex-vivo (cell) · in-vivo (LNP) · in-vivo (AAV)
By Application	Oncology · rare / genetic disease · immunology & infectious disease
By End User	Hospitals · pharma / biotech · CDMOs · academia
By Stage	Approved · clinical · preclinical
By Business Model	Product sales · CDMO services · licensing

TABLE OF CONTENTS — PARTS & CHAPTERS

The full report is organised into nine parts across 53 chapters, listed below. Detailed sub-headings, country tables and directories are provided in the full report.

© Anew Market Dynamics

Part V — Company, Competition, Patent and Project Intelligence

Part VI — Sustainability, ESG, SDG, Climate and Natural-Capital Intelligence

Part VII — Supply Chain, Policy, Legal, Economics and Finance

Part VIII — Scenario, Future Intelligence and Final Due Diligence Verdict

Part IX — Annexes, Directories and Reference Material

COMPETITIVE & INVESTMENT SNAPSHOT

The competitive field is led by gene-editing pure-plays and their large-pharma partners. Deal activity — pharma partnerships, delivery licensing and next-generation-editor platforms — signals a field consolidating around validated delivery and high-specificity editing.

Representative players profiled in the full report:

CRISPR Therapeutics AG · Vertex Pharmaceuticals Incorporated · Intellia Therapeutics, Inc. · Editas Medicine, Inc. · Beam Therapeutics Inc. · Prime Medicine, Inc. · Caribou Biosciences, Inc. · and further profiled players across developers and large-pharma partners.

Investment intelligence: venture, infrastructure, development, climate and blended finance, green bonds and sustainability-linked loans — culminating in a bankability assessment and a conditional investment view.

© Anew Market Dynamics

KEY QUESTIONS THIS REPORT ANSWERS

- How large is the global CRISPR gene editing therapeutics market, and how fast will it grow to 2032?
- Which regions, countries and segments offer the strongest risk-adjusted opportunity?
- How does in-vivo delivery change value versus ex-vivo approaches?
- Who leads, and where is the competitive and patent white space?
- Is the investment case bankable — and under what conditions?
- How does the category align with the SDGs, equitable access and governance expectations?

WHY ANMD — THE DIFFERENCE

Most market studies stop at units and revenue. This report is built as a sustainability due diligence instrument — fusing market sizing with ESG, SDG, climate, water and natural-capital intelligence and a decision-ready bankability view in a single architecture.

- **Triangulated sizing** — every market read three ways so value, volume and the physical-unit views reconcile rather than conflict.
- **Region-honest forecasting** — Latin America, Africa and the Middle East reported in full, never hidden inside Rest of World, every forecast resolved to the 2025 base year.
- **Integrated evidence base** — company, patent and project databases linked to the analysis, with published-filing patents and FTO treated as an indicator, not a legal conclusion.
- **No-fabrication discipline** — every estimate carries a data-confidence rating and disclosed sources; gaps are flagged for further diligence, never filled with invented numbers.
- **Anti-greenwashing rigour** — SDG-washing and greenwashing screens plus claim-substantiation checks built into the ESG and project analysis.
- **Decision-first structure** — 9 Parts and 53 Chapters culminating in stakeholder playbooks and a clear, conditional investment view.

WHO SHOULD BUY THIS REPORT

Investors, biopharma, CDMOs, hospitals, payers, regulators, lenders and policymakers, and strategic corporate planners and decision-makers.

Access the Full Report

The complete report delivers all 53 chapters in full, with every sub-heading, country table, company and patent directory, forecast model and due diligence checklist.

Purchase at **www.anewmarketdynamics.com** · Standard & Premium licences · Single-Site (SSL) and Global-Site (GSL) options at checkout.

Want the Complete Detailed Table of Contents?

This prospectus lists the nine parts and 53 chapters. The complete detailed table of contents — every sub-heading, country table, exhibit, company and patent directory and annex — is available on request to registered users. To receive it, register with your official company email at **www.anewmarketdynamics.com**. The full detailed table of contents will be sent directly to your registered company email address.

© Anew Market Dynamics